Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed.

Ferrari S, Perut F, Fagioli F, Brach Del Prever A, Meazza C, Parafioriti A, Picci P, Gambarotti M, Avnet S, Baldini N, Fais S.

J Transl Med. 2013 Oct 24;11:268. doi: 10.1186/1479-5876-11-268.

2.

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, Federici C, Iessi E, Parmiani G, Arancia G, Belardelli F, Fais S.

J Natl Cancer Inst. 2004 Nov 17;96(22):1702-13.

4.

Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.

Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, Longhi A, Manfrini M, Bertoni F, Rimondini S, Monti C, Forni C.

Oncol Rep. 2000 Mar-Apr;7(2):339-46.

PMID:
10671683
5.

Proton pump inhibitors may reduce tumour resistance.

De Milito A, Fais S.

Expert Opin Pharmacother. 2005 Jun;6(7):1049-54. Review.

PMID:
15957961
6.

Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.

Bacci G, Ferrari S, Bertoni F, Picci P, Bacchini P, Longhi A, Donati D, Forni C, Campanacci L, Campanacci M.

Clin Orthop Relat Res. 2001 May;(386):186-96.

PMID:
11347833
7.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

8.

Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma.

Seki K, Yoshikawa H, Shiiki K, Hamada Y, Akamatsu N, Tasaka K.

Cancer Chemother Pharmacol. 2000;45(3):199-206.

PMID:
10663637
9.
10.

Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma.

Rha SY, Chung HC, Gong SJ, Shim KY, Ahn JB, Yang WI, Shin KH, Yoo NC, Kim JH, Roh JK, Lee CI, Kim BS.

Oncol Rep. 1999 May-Jun;6(3):631-7.

PMID:
10203605
11.

Arsenic trioxide inhibits the growth of adriamycin resistant osteosarcoma cells through inducing apoptosis.

Zhao H, Guo W, Peng C, Ji T, Lu X.

Mol Biol Rep. 2010 Jun;37(5):2509-15. doi: 10.1007/s11033-009-9765-2. Epub 2009 Aug 22.

PMID:
19701692
12.

pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.

De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S.

Int J Cancer. 2010 Jul 1;127(1):207-19. doi: 10.1002/ijc.25009.

13.

Neoadjuvant chemotherapy for the treatment of osteosarcoma of the extremities: excellent response of the primary tumor to preoperative treatment with methotrexate, cisplatin, adriamycin, and ifosfamide. Preliminary results.

Bacci G, Picci P, Ferrari S, Sangiorgi L, Mercuri M, Bertoni F, Brach del Prever A, Tienghi A, Mancini A, Comandone A, et al.

Chir Organi Mov. 1995 Jan-Mar;80(1):1-10. English, Italian.

PMID:
7641534
14.

Tumor acidity, chemoresistance and proton pump inhibitors.

De Milito A, Fais S.

Future Oncol. 2005 Dec;1(6):779-86. Review.

PMID:
16556057
15.

Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin.

Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, D'Ilio S, Lugini L, Violante N, Azzarito T, Majorani C, Brambilla D, Fais S.

PLoS One. 2014 Feb 6;9(2):e88193. doi: 10.1371/journal.pone.0088193. eCollection 2014.

16.

Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.

Fromigué O, Hamidouche Z, Marie PJ.

J Pharmacol Exp Ther. 2008 May;325(2):595-600. doi: 10.1124/jpet.108.136127. Epub 2008 Feb 5.

17.

Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.

Castro-Gamero AM, Borges KS, da Silva Silveira V, Lira RC, de Paula Gomes Queiroz R, Valera FC, Scrideli CA, Umezawa K, Tone LG.

Anticancer Drugs. 2012 Jul;23(6):638-50. doi: 10.1097/CAD.0b013e328350e835.

PMID:
22382389
18.

Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism.

Fais S.

J Intern Med. 2010 May;267(5):515-25. doi: 10.1111/j.1365-2796.2010.02225.x. Review.

19.

Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin.

Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, Brach del Prever A, Tienghi A, Comandone A, Campanacci M.

J Clin Oncol. 1998 Feb;16(2):658-63.

PMID:
9469355
20.

Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.

Takeshita H, Kusuzaki K, Ashihara T, Gebhardt MC, Mankin HJ, Hirasawa Y.

J Bone Joint Surg Am. 2000 Jul;82-A(7):963-9.

PMID:
10901311
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk